hyperCORE International Appoints Nicholas Focil as New President to Drive Global Clinical Research Forward

hyperCORE International has announced Nicholas Focil as its new president, a decision that underscores the network's commitment to strengthening its position in the global clinical research arena. Focil, who brings nearly two decades of experience in clinical operations leadership, strategic partnerships, and expansion into emerging markets, is expected to play a pivotal role in advancing hyperCORE's mission. His background as the founder and CEO of FOMAT Medical Research, a charter member of hyperCORE International, highlights his dedication to ethical, high-quality, and diverse clinical data.

Focil's leadership comes at a time when the clinical research industry is increasingly focusing on diversity, innovation, and patient-centered care. His previous work, including pioneering roles in pre-pivotal diabetes device trials and efforts to promote trial diversity and community engagement, aligns with hyperCORE's objectives. The outgoing president, Carlos Orantes, praised Focil's appointment as a milestone for the network, expressing confidence in his ability to lead hyperCORE towards continued excellence.

In his statement, Focil expressed gratitude towards Orantes and previous presidents for their contributions, emphasizing the strong foundation they have built. He outlined his vision for hyperCORE, focusing on enhancing site capabilities, expanding trial reach, and delivering diverse, high-quality research. Focil's appointment is seen as a strategic move to capitalize on the dynamic growth and momentum in the clinical research sector, promising to bring innovative solutions and operational excellence to the forefront of hyperCORE's endeavors.

hyperCORE International, since its inception in 2019, has established itself as a leading partner site network, with over 80 active trial sites across five countries and two continents. The network's commitment to advancing clinical research through safe, ethical, and timely studies, coupled with efficient enrollment and superior retention, positions it as a key player in the industry. Focil's leadership is anticipated to further these goals, driving hyperCORE's impact in the global clinical research space.